series-c-plus
Stage
2013
Founded
7
Investors
About
Abivax is a clinical-stage biotechnology company developing therapeutics that modulate the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate, obefazimod, is in Phase 3 clinical trials for ulcerative colitis and Phase 2 for Crohn's disease.
Explore Abivax's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.